Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP).
BACKGROUND: The past 5 years have seen a proliferation of new treatments for atopic dermatitis (AD). We analyzed recent drug survival data for cyclosporine in this setting. Because the Spanish National Healthcare system requires patients with AD to be treated with cyclosporine before they can be pre...
| Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2024 |
| País: | España |
| Institución: | Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL) |
| Repositorio: | r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante |
| OAI Identifier: | oai:isabial.fundanetsuite.com:p9875 |
| Acceso en línea: | https://isabial.portalinvestigacion.com/publicaciones9875 https://www.sciencedirect.com/science/article/pii/S0001731023006087?via%3Dihub |
| Access Level: | acceso abierto |
| Palabra clave: | Análisis de supervivencia Atopic dermatitis Ciclosporina Cyclosporine Dermatitis atópica Survival analysis |
| id |
ES_73a6ca030eb47dceaa23a00eb3fc68d9 |
|---|---|
| oai_identifier_str |
oai:isabial.fundanetsuite.com:p9875 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP).Couselo-Rodríguez CBatalla ACarrascosa JMChicharro PGonzález-Quesada Ade la Cueva PGiménez-Arnau AMGilaberte YRodríguez-Serna MMontero-Vilchez TRuiz-Villaverde RElosua-González MSilvestre-Salvador JFMunera-Campos MSánchez-Pérez JCarretero GMauleón-Fernández CCurto-Barredo LBallano-Ruiz ABotella-Estrada RArias-Santiago SNavarro-Triviño FJRoustan-Gullón GBetlloch IDel Alcázar EAbalde-Pintos MTSuárez-Perez JGarcía-Doval IDescalzo MÁFlórez ÁAnálisis de supervivenciaAtopic dermatitisCiclosporinaCyclosporineDermatitis atópicaSurvival analysisBACKGROUND: The past 5 years have seen a proliferation of new treatments for atopic dermatitis (AD). We analyzed recent drug survival data for cyclosporine in this setting. Because the Spanish National Healthcare system requires patients with AD to be treated with cyclosporine before they can be prescribed other systemic treatments, drug survival for cyclosporine may be shorter than in other diseases. MATERIAL AND METHOD: Multicenter, observational, prospective cohort study using data from the Spanish Atopic Dermatitis Registry (BIOBADATOP). Data from the Spanish Registry of Systemic Treatments in Psoriasis (BIOBADADERM) were used to create a comparison cohort. RESULTS: We analyzed data for 130 patients with AD treated with cyclosporine (median drug survival, 1 year). Median cyclosporine survival in the psoriasis comparison group (150 patients) was 0.37 years. Drug survival was significantly longer in AD than in psoriasis (P<.001). CONCLUSION: Drug survival of cyclosporine in the BIOBADATOP registry is similar to that described in other series of patients with AD and longer than that observed in the BIOBADADERM psoriasis registry.ELSEVIER ESPANA2024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://isabial.portalinvestigacion.com/publicaciones9875https://www.sciencedirect.com/science/article/pii/S0001731023006087?via%3DihubActas Dermo-SifiliograficasISSN: 00017310ISSNe: 15782190reponame:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicanteinstname:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)Españolinfo:eu-repo/semantics/openAccessoai:isabial.fundanetsuite.com:p98752026-06-12T10:20:37Z |
| dc.title.none.fl_str_mv |
Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP). |
| title |
Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP). |
| spellingShingle |
Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP). Couselo-Rodríguez C Análisis de supervivencia Atopic dermatitis Ciclosporina Cyclosporine Dermatitis atópica Survival analysis |
| title_short |
Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP). |
| title_full |
Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP). |
| title_fullStr |
Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP). |
| title_full_unstemmed |
Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP). |
| title_sort |
Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP). |
| dc.creator.none.fl_str_mv |
Couselo-Rodríguez C Batalla A Carrascosa JM Chicharro P González-Quesada A de la Cueva P Giménez-Arnau AM Gilaberte Y Rodríguez-Serna M Montero-Vilchez T Ruiz-Villaverde R Elosua-González M Silvestre-Salvador JF Munera-Campos M Sánchez-Pérez J Carretero G Mauleón-Fernández C Curto-Barredo L Ballano-Ruiz A Botella-Estrada R Arias-Santiago S Navarro-Triviño FJ Roustan-Gullón G Betlloch I Del Alcázar E Abalde-Pintos MT Suárez-Perez J García-Doval I Descalzo MÁ Flórez Á |
| author |
Couselo-Rodríguez C |
| author_facet |
Couselo-Rodríguez C Batalla A Carrascosa JM Chicharro P González-Quesada A de la Cueva P Giménez-Arnau AM Gilaberte Y Rodríguez-Serna M Montero-Vilchez T Ruiz-Villaverde R Elosua-González M Silvestre-Salvador JF Munera-Campos M Sánchez-Pérez J Carretero G Mauleón-Fernández C Curto-Barredo L Ballano-Ruiz A Botella-Estrada R Arias-Santiago S Navarro-Triviño FJ Roustan-Gullón G Betlloch I Del Alcázar E Abalde-Pintos MT Suárez-Perez J García-Doval I Descalzo MÁ Flórez Á |
| author_role |
author |
| author2 |
Batalla A Carrascosa JM Chicharro P González-Quesada A de la Cueva P Giménez-Arnau AM Gilaberte Y Rodríguez-Serna M Montero-Vilchez T Ruiz-Villaverde R Elosua-González M Silvestre-Salvador JF Munera-Campos M Sánchez-Pérez J Carretero G Mauleón-Fernández C Curto-Barredo L Ballano-Ruiz A Botella-Estrada R Arias-Santiago S Navarro-Triviño FJ Roustan-Gullón G Betlloch I Del Alcázar E Abalde-Pintos MT Suárez-Perez J García-Doval I Descalzo MÁ Flórez Á |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
| dc.subject.none.fl_str_mv |
Análisis de supervivencia Atopic dermatitis Ciclosporina Cyclosporine Dermatitis atópica Survival analysis |
| topic |
Análisis de supervivencia Atopic dermatitis Ciclosporina Cyclosporine Dermatitis atópica Survival analysis |
| description |
BACKGROUND: The past 5 years have seen a proliferation of new treatments for atopic dermatitis (AD). We analyzed recent drug survival data for cyclosporine in this setting. Because the Spanish National Healthcare system requires patients with AD to be treated with cyclosporine before they can be prescribed other systemic treatments, drug survival for cyclosporine may be shorter than in other diseases. MATERIAL AND METHOD: Multicenter, observational, prospective cohort study using data from the Spanish Atopic Dermatitis Registry (BIOBADATOP). Data from the Spanish Registry of Systemic Treatments in Psoriasis (BIOBADADERM) were used to create a comparison cohort. RESULTS: We analyzed data for 130 patients with AD treated with cyclosporine (median drug survival, 1 year). Median cyclosporine survival in the psoriasis comparison group (150 patients) was 0.37 years. Drug survival was significantly longer in AD than in psoriasis (P<.001). CONCLUSION: Drug survival of cyclosporine in the BIOBADATOP registry is similar to that described in other series of patients with AD and longer than that observed in the BIOBADADERM psoriasis registry. |
| publishDate |
2024 |
| dc.date.none.fl_str_mv |
2024 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
https://isabial.portalinvestigacion.com/publicaciones9875 https://www.sciencedirect.com/science/article/pii/S0001731023006087?via%3Dihub |
| url |
https://isabial.portalinvestigacion.com/publicaciones9875 https://www.sciencedirect.com/science/article/pii/S0001731023006087?via%3Dihub |
| dc.language.none.fl_str_mv |
Español |
| language_invalid_str_mv |
Español |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
ELSEVIER ESPANA |
| publisher.none.fl_str_mv |
ELSEVIER ESPANA |
| dc.source.none.fl_str_mv |
Actas Dermo-Sifiliograficas ISSN: 00017310 ISSNe: 15782190 reponame:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante instname:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL) |
| instname_str |
Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL) |
| reponame_str |
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante |
| collection |
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869410825357230080 |
| score |
15,81155 |